Sun Pharma Q1 Results Highlights: Net Profit Surges 40% YoY to ₹2,836 Cr

Sun Pharmaceutical Industries announced that its net profit for the first quarter of fiscal year 2025 increased by 40% year-on-year to ₹2,836 crore. The company's revenue for the April-June quarter grew by 6%, reaching ₹12,653 crore.

Sun Pharma Q1 Results Highlights

On August 1, Sun Pharmaceutical Industries announced that its net profit for the first quarter of fiscal year 2025 increased by 40% year-on-year to ₹2,836 crore, up from ₹2,023 crore in the same quarter of the previous year, surpassing market expectations. The company's revenue for the April-June quarter grew by 6%, reaching ₹12,653 crore compared to ₹11,941 crore a year earlier.

On an adjusted basis, the net profit for the first quarter rose approximately 21% year-on-year. In the notes accompanying the financial statement, Sun Pharma mentioned that the results are not directly comparable to previous periods due to the acquisition of a 60% stake in Vivaldis Health and Foods Pvt Ltd for ₹143 crore during the same quarter of the previous year.

A Moneycontrol survey of 13 brokerage firms had predicted Sun Pharma's Q1 net profit to be ₹2,579 crore and revenue to be ₹12,904 crore, supported by robust sales in the US market, particularly from the cancer drug Revlimid, and strong performance in the domestic market driven by chronic therapies.

Sun Pharma's sales of formulations in India increased by 16.4% to ₹4,144 crore, making up approximately 33.1% of total consolidated sales. The company introduced six new products in the Indian market during this quarter. In the US, formulation sales slightly decreased to $466 million, down 1% year-on-year, but still represented over 31.1% of total consolidated sales.

Global specialty sales rose by 14.7% to $266 million, accounting for 17.7% of total sales. Sales in emerging markets grew by 8.8% to $284 million, while sales in the rest of the world declined by 2.9% to $190 million.

Research and development expenses for the quarter increased to ₹794 crore, up from ₹680 crore in Q1 FY24. The company's EBITDA for the April-June quarter grew by 8.3% year-on-year to ₹3,608 crore, which includes other operating revenues. The EBITDA margin improved to 28.5% from 27.9% in the same period last year.

Sun Pharma Industries Ltd Management Commentary

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, "Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe, and the completion of the acquisition of Taro minority shares. These steps advance our innovative as well as generic business offerings, and will help us serve patients better."

About Sun Pharma

Sun Pharmaceutical Industries Ltd (Sun Pharma) is a specialty pharmaceutical company providing a diverse range of pharmaceutical formulations, including branded generics and generic pharmaceuticals. Its product portfolio covers treatments for psychiatric, neurological, nephrological, gastroenterological, orthopedic, ophthalmologic, and cardiovascular diseases and disorders.

The company is involved in product development, process chemistry, and the manufacturing of complex formulations, active pharmaceutical ingredients (APIs), and over-the-counter products. It offers medications in various dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Sun Pharma operates manufacturing facilities across North America, Latin America, EMEA, and the Asia Pacific region. The company is headquartered in Mumbai, Maharashtra, India.